UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of January 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 17 January 2024, London UK
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, TRANSMISSION
DISTRIBUTION OR FORWARDING, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN
PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE
REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION IN WHICH SUCH
PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE
UNLAWFUL.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN
OFFER OF SECURITIES IN ANY JURISDICTION.
GSK completes sale of shares in Haleon
GSK plc (LSE/NYSE: GSK) today announced that, further to its
announcement on 16 January 2024, GSK has agreed to sell 300m
ordinary shares in Haleon plc ("Haleon") at a price of 326 pence per share (the
"Placing
Shares"), raising gross
proceeds of approximately £978m (the "Placing").
Following settlement of the Placing, GSK will hold approximately
385m ordinary shares in Haleon, representing approximately 4.2% of
the issued share capital of Haleon.
GSK and Pfizer Inc. (which holds a 32% stake in Haleon), have each
undertaken not to dispose of any further shares in Haleon for a
period of 60 days following settlement of the Placing, subject to
certain customary exceptions and waiver by BofA Securities and
Citigroup Global Markets Limited.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Sarah
Clements
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
Alison
Hunt
|
+1 540
742 3391
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Camilla
Campbell
|
+44 (0)
7803 050238
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Disclaimer
The contents of this announcement have been prepared by and are the
sole responsibility of GSK.
This announcement is for information purposes only and is not
intended to and does not constitute or form part of any offer or
invitation to purchase, otherwise acquire, subscribe for, sell,
otherwise dispose of or issue, or any solicitation of any offer to
sell, otherwise dispose of, issue, purchase, otherwise acquire or
subscribe for, any security.
Information regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors' in the Company's Annual Report on Form 20-F for 2022
and GSK's Q3 Results for 2023.
This Announcement does not constitute a recommendation to acquire
any ordinary shares in Haleon. This Announcement does not identify
or suggest, or purport to identify or suggest, the risks (direct or
indirect) that may be associated with an investment in Haleon. Any
investment must be made solely on the basis of publicly available
information, which has not been independently verified by Citigroup
Global Markets Limited ("Citi") or Merrill Lynch International
("BofA
Securities").
No offer
Neither this announcement nor anything contained herein shall form
the basis of, or be relied upon in connection with, any offer or
purchase whatsoever in any jurisdiction and shall not constitute or
form part of an offer to sell or the solicitation of an offer to
buy any securities in the United States or in any other
jurisdiction. The securities referred to herein may not be offered
or sold in the United States absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the
"Securities
Act"). The securities referred
to herein may not be deposited in an unrestricted depositary
receipt facility for 40 days following the commencement of the
Offering or for so long as the securities are "restricted
securities" within the meaning of Rule 144 under the Securities
Act. GSK does not intend to register any part of the Offering in
the United States or to conduct a public offering in the United
States of the shares to which this announcement
relates.
This announcement does not constitute a prospectus or an offer or
invitation to purchase securities. This announcement is only
addressed to, and directed at, persons who are "qualified
investors", being persons falling within the meaning of Article
2(e) of Regulation (EU) 2017/1129 as it forms part of domestic law
in the United Kingdom by virtue of the European Union (Withdrawal)
Act 2018 and who: (a) (i) have professional experience in matters
relating to investments falling within the definition of
"investment professionals" in article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005, as
amended (the "Order"); or (ii) are persons falling within article
49(2)(a) to (d) ("high net worth companies, unincorporated
associations, etc") of the Order; or (b) persons to whom it may
otherwise lawfully be communicated, (each such persons in (a) and
(b) together being referred to as "Relevant
Persons").
In addition, this announcement is not being distributed, nor has it
been approved for the purposes of Section 21 of the Financial
Services and Markets Act 2000 ("FSMA"), by a person authorised under
FSMA.
This document is directed only at Relevant Persons and must not be
acted on or relied on by persons who are not Relevant Persons.
Under no circumstances should persons who are not Relevant Persons
rely or act upon the contents of this announcement. Any investment
or investment activity to which this announcement relates in the
United Kingdom is available only to, and will be engaged only with,
Relevant Persons. Persons distributing this announcement must
satisfy themselves that it is lawful to do so.
The Placing and the distribution of this announcement and other
information in connection with the Placing in certain jurisdictions
may be restricted by law. No action has been taken that would
permit the Placing or distribution of this announcement in any
jurisdiction where action for such purpose is required. Persons
into whose possession any document or other information referred to
herein comes should inform themselves about and observe any such
restriction. Any failure to comply with these restrictions may
constitute a violation of the securities laws of any such
jurisdiction.
In connection with the Placing, Citi, BofA Securities and their
respective affiliates may take up a portion of the Placing Shares
as a principal position at any stage at their sole discretion,
inter alia, to take account of the objectives of GSK, MiFID II/ UK
MiFID II requirements and in accordance with allocation policies
and in that capacity may retain, purchase, sell, offer to sell for
their own accounts such Placing Shares and other securities of the
Company or related investments in connection with the Placing or
otherwise. Accordingly, references in this announcement to
the Placing Shares being sold, offered, subscribed, acquired,
placed or otherwise dealt in should be read as including any issue
or offer to, or subscription, acquisition, placing or dealing by,
Citi, BofA Securities or their respective affiliates acting in such
capacity. In addition, Citi, BofA Securities and their
respective affiliates may enter into financing arrangements
(including swaps or contracts for differences) with investors in
connection with which Citi, BofA Securities and their respective
affiliates may from time to time acquire, hold or dispose of
Placing Shares. Neither Citi nor BofA Securities intends to
disclose the extent of any such investment or transactions
otherwise than in accordance with any legal or regulatory
obligations to do so.
Any communications that a transaction is or that the book is
"covered" (i.e. indicated demand from investors in the book equals
or exceeds the amount of the securities being offered) is not any
indication or assurance that the book will remain covered or that
the transaction and securities will be fully distributed by Citi or
BofA Securities.
None of Citi, BofA Securities or any of their or their respective
affiliates' directors, officers, employees, advisers or agents
accepts any responsibility or liability whatsoever for or makes any
representation or warranty, express or implied, as to the truth,
accuracy or completeness of the information in this announcement
(or whether any information has been omitted from the announcement)
or any other information relating to Haleon, GSK, their respective
subsidiaries or associated companies, whether written, oral or in a
visual or electronic form, and howsoever transmitted or made
available or for any loss howsoever arising from any use of this
announcement or its contents or otherwise arising in connection
therewith.
Citi and BofA Securities are each authorised by the Prudential
Regulatory Authority and regulated in the United Kingdom by the
Prudential Regulation Authority and the Financial Conduct
Authority, and are acting for GSK and for no one else in connection
with the Placing and will not be responsible to anyone other than
GSK for providing the protections afforded to their customers or
for affording advice in relation to the Placing, the contents of
this announcement or any transaction, arrangement or other matter
referred to in this announcement.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: January
17, 2024
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
